KRAS and neoplasm: An emerging body of evidence underscores the importance of precise patient selection, suggesting that the anatomical site, genomic factors (e.g., KRAS and TP53 mutations), primary tumour origin (colon versus rectum), and clinical variables significantly influence treatment outcomes [31,32,33].